Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)

This study has been withdrawn prior to enrollment.
(Study halted prior to enrollment of first participant)
Sponsor:
Collaborators:
PharmaNet
Nextrials, Inc.
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01093105
First received: March 24, 2010
Last updated: February 19, 2014
Last verified: February 2014

March 24, 2010
February 19, 2014
Not Provided
Not Provided
  • To measure the change from baseline in growth parameters (eg, weight gain, linear growth, head circumference). [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To determine the onset date of inadequate oral nutrition, hydration, and/or ventilation as a biomarker for survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01093105 on ClinicalTrials.gov Archive Site
  • To assess the change from baseline in clinical parameters of GLD disease progression from a standardized infant neurological examination and infant distress scales. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To assess the change from baseline in clinical parameters described in Hagberg's clinical staging. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To measure the time to absolute survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • To assess the AE experience in this patient population [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
An Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (GLD)
A Multicenter, Prospective, Longitudinal, Observational Study of Pediatric Subjects With Globoid Cell Leukodystrophy (Krabbe Disease)

The objective of this study is to evaluate the natural history of disease progression in infants with globoid cell leukodystrophy (GLD).

This study is being conducted to gather prospective data on disease progression in infants diagnosed with GLD. This study will be performed using protocol-defined, standardized assessments including clinical, developmental, and neurologic measures. All study visits will be conducted in the subject's home. No travel to the study site is necessary.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Subjects with a documented diagnosis of GLD and clinical signs and symptoms consistent with that diagnosis

Leukodystrophy, Globoid Cell
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
Not Provided

Inclusion Criteria:

Subjects must meet all of the following criteria to be considered eligible for this study:

  1. The subject has a documented diagnosis of GLD as evidenced by GALC enzyme activity or a GALC genotype that is predictive of GLD.
  2. The subject must have clinical signs and symptoms consistent with the diagnosis of infantile GLD including at least 2 of the following:

    1. Chronic difficulty with feeding or unexplained irritability or "fisting" or other signs of abnormal increased tone
    2. CT or MRI imaging, if performed during diagnostic evaluation prior to enrollment, consistent with GLD
    3. Failure to meet at least 2 age-specific developmental milestones consistent with GLD
    4. Loss of deep tendon reflexes or abnormal visual fixation or optic atrophy
  3. The subject has documented onset of signs and symptoms consistent with GLD at <12 months of age and is <21 months of age at time of study entry.
  4. The subject was born at a gestational age of 35-41 weeks.
  5. The subject had a birth weight of ≥2 kg.
  6. At study entry, the subject must be able to maintain oral nutrition and hydration without the use of supportive measures, defined as use of a feeding tube.
  7. At study entry, the subject must be able to maintain ventilation without the use of invasive supportive measures, defined as use of a breathing tube.
  8. The subject must be able, in the opinion of the Investigator, to accommodate the protocol requirements, including feasibility of study visits.
  9. The subject's parent(s) or legal guardian must have voluntarily signed an Institutional Review Board/Independent Ethics Committee-approved informed consent form after all relevant aspects of the study have been explained and discussed with the subject's parent(s), or legal guardian.

Exclusion Criteria: Subjects who meet any of the following criteria are not eligible for this study:

  1. The subject has neurologic, hearing or vision impairment, difficulty swallowing or feeding, respiratory complications, behavioral disturbances, or other medical conditions that are not due to GLD and are likely to confound the scientific integrity or interpretation of study assessments, as determined by the Investigator.
  2. The subject has received treatment with any investigational drug or a device within the 30 days prior to study enrollment through study completion.
  3. The subject has received a cord blood or bone marrow transplant or is planning to receive one during the study.
  4. The subject's parent(s) or legal guardian is unable to understand the nature, scope, and possible consequences of the study, or does not agree to comply with the protocol defined schedule of assessments.
Both
up to 21 Months
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01093105
HGT-GLD-056
No
Shire
Shire
  • PharmaNet
  • Nextrials, Inc.
Study Director: Lawrence Charnas, MD, PhD Shire Human Genetic Therapies, Inc.
Shire
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP